1 Ocak 2019 Dergi makalesi Açık Erişim

Oran, D. C.; Lokumcu, T.; Inceoglu, Y.; Akolpoglu, M. B.; Albayrak, O.; Bal, T.; Kurtoglu, M.; Erkan, M.; Can, F.; Bagci-Onder, T.; Kizilel, S.

Dublin Core

<?xml version='1.0' encoding='utf-8'?>
<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Oran, D. C.</dc:creator>
  <dc:creator>Lokumcu, T.</dc:creator>
  <dc:creator>Inceoglu, Y.</dc:creator>
  <dc:creator>Akolpoglu, M. B.</dc:creator>
  <dc:creator>Albayrak, O.</dc:creator>
  <dc:creator>Bal, T.</dc:creator>
  <dc:creator>Kurtoglu, M.</dc:creator>
  <dc:creator>Erkan, M.</dc:creator>
  <dc:creator>Can, F.</dc:creator>
  <dc:creator>Bagci-Onder, T.</dc:creator>
  <dc:creator>Kizilel, S.</dc:creator>
  <dc:date>2019-01-01</dc:date>
  <dc:description>Type 1 diabetes (T1D) is an autoimmune disease characterized by destruction of pancreatic beta cells. One of the promising therapeutic approaches in T1D is the transplantation of islets; however, it has serious limitations. To address these limitations, immunotherapeutic strategies have focused on restoring immunologic tolerance, preventing transplanted cell destruction by patients' own immune system. Macrophage-derived chemokines such as chemokine-ligand-22 (CCL22) can be utilized for regulatory T cell (Treg) recruitment and graft tolerance. Stellate cells (SCs) have various immunomodulatory functions: recruitment of Tregs and induction of T-cell apoptosis. Here, we designed a unique immune-privileged microenvironment around implantable islets through overexpression of CCL22 proteins by SCs. We prepared pseudoislets with insulin-secreting mouse insulinoma-6 (MIN6) cells and human SCs as a model to mimic naive islet morphology. Our results demonstrated that transduced SCs can secrete CCL22 and recruit Tregs toward the implantation site in vivo. This study is promising to provide a fundamental understanding of SC-islet interaction and ligand synthesis and transport from SCs at the graft site for ensuring local immune tolerance. Our results also establish a new paradigm for creating tolerable grafts for other chronic diseases such as diabetes, anemia, and central nervous system (CNS) diseases, and advance the science of graft tolerance.</dc:description>
  <dc:identifier>https://aperta.ulakbim.gov.trrecord/71561</dc:identifier>
  <dc:identifier>oai:zenodo.org:71561</dc:identifier>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>http://www.opendefinition.org/licenses/cc-by</dc:rights>
  <dc:source>MATERIALS TODAY BIO 2</dc:source>
  <dc:title>Engineering human stellate cells for beta cell replacement therapy promotes in vivo recruitment of regulatory T cells</dc:title>
  <dc:type>info:eu-repo/semantics/article</dc:type>
  <dc:type>publication-article</dc:type>
</oai_dc:dc>